Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
about
Transcriptional Targeting in Cancer Gene TherapyToxin-based therapeutic approachesProgress and problems with the use of suicide genes for targeted cancer therapyAdenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer.A polymer library approach to suicide gene therapy for cancer.Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET.Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.Non-invasive molecular imaging of prostate cancer lymph node metastasis.Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancerAdvances in preclinical investigation of prostate cancer gene therapy.Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters.AEG-1 promoter-mediated imaging of prostate cancer.Prodrugs for improving tumor targetability and efficiency.Transcriptionally targeted gene therapy to detect and treat cancer.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification systemNovel gene-directed enzyme prodrug therapies against prostate cancer.A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.Manipulation of adenovirus interactions with host factors for gene therapy applications.Cancer imaging: Gene transcription-based imaging and therapeutic systems.A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach.A dual-targeted lentiviral vector homing in on prostate bone metastasesEvaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging.Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to AntiandrogensCell-specific expression of the analgesic-antitumor peptide coding sequence under the control of the human α-fetoprotein gene promoter and enhancer.Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice.Improving adenoviral vectors and strategies for prostate cancer gene therapy
P2860
Q24791038-56E05D6D-89C6-4796-9104-B1BADE3D0CC8Q27013664-7E4E94AD-11F9-4637-BE17-066A23D0C15DQ28262370-9AAC43D5-0C46-465F-A290-3D3F2660DAE1Q30492895-95375FD4-89C3-432C-9CAA-1EFD6525E1D9Q33208598-A9EE5FCF-69E7-4F81-8ACF-BF2147E5BA2AQ33416415-F0C0DDD0-F4CE-421A-BC92-58A205AA74E8Q33507490-777FD0A2-6220-4F5B-A4D7-E676133854C1Q33557567-352D37D8-D0DD-4904-9FD0-94E33A8F7212Q33647321-A713FCFC-59FF-41B5-9B17-C91A79CC6A4CQ33650205-45D315BF-74D4-46D7-BBB5-DC9390BB9626Q33677054-6626AD5A-2A92-46D6-8FCE-1AA0736D6053Q33952065-FF87A4F6-2DFA-442B-B68C-834127A604D6Q34522714-C462CDD1-6021-4B99-B8C3-C289C83D1E14Q35095165-DE98214E-1471-464A-B0D4-9BF64698187FQ35558678-DF52F66A-71E8-4A54-ADEE-BBFE7BB9C189Q36258513-85FB4DEC-C175-4A55-B6F0-70075DC65A70Q36512533-0FF26319-0BCA-4C5A-A601-314352BF6514Q36543076-4B5E08D4-B957-4618-AD9E-C9A65AF69D4EQ36659285-03EE8AA5-A645-4732-8C69-DCFA57C3D3FCQ37984486-4B5914D3-2E48-4904-B485-E0DCDAEDB5DFQ37986315-3ED7F9DD-19C4-4687-95A4-206EBEC31929Q38817672-50A256ED-5B86-4F56-9D5B-B31A24456197Q39516198-FD2A06AD-F127-474A-9ADE-6DF84C7AAFE8Q39618679-AED5CABB-D2F2-4F7F-A8A5-3502D2008707Q39732460-DF420BDD-6E0F-432F-9D5D-C0AD8279723CQ39942987-C43F52E9-1BBD-4F75-B494-78E203B4329CQ40008139-97352195-02F9-4DF7-BFA1-094823307DACQ40395122-AAC230EB-9114-49EC-B88A-0DA099AC8CA9Q40519641-FF208F95-2F8D-4E90-ABF0-E9B1CB57CF84Q41202972-A0776D10-E530-461B-9090-4B5F772C65CFQ41828019-2C18F005-2207-4B1E-A44F-B5340F6B2185Q44124765-7F164EDD-4805-4604-9404-1E03CFAED76BQ46169454-3E0338A0-E48B-4FD0-AD2B-AC84B4CE8322Q58801177-CF891278-5EA2-43C6-99CA-C9D7979A0071
P2860
Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@en
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@nl
type
label
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@en
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@nl
prefLabel
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@en
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@nl
P2093
P2860
P356
P1433
P1476
Chimeric PSA enhancers exhibit ...... e cancer gene therapy vectors.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3301549
P577
2001-09-01T00:00:00Z
P5875
P6179
1052960196